PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y, Chen W, Xu ZP, Gu W. · 2019
Read PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. by Wu Y, Chen W, Xu ZP, Gu W. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6718566.txt.
Introduction
Wu and co-authors reviewed where the protein PD-L1 sits in cells and why it matters for cancer therapy. PD-L1 helps tumors dodge the immune system, and antibody drugs that block it have helped some patients. Yet many solid tumors respond poorly. The authors argue that PD-L1 hidden inside cells is part of the reason.
PD-L1 on the cell surface can be blocked by antibodies. PD-L1 inside the cell cannot, and it does other jobs linked to poor outcomes. Switching the gene off may beat blockade, since it cuts supply everywhere. Silencing PD-L1 in immune cells may also free T cells to clear tumors.
Catalog record
| CREATOR | Wu Y, Chen W, Xu ZP, Gu W. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition By Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2019.02022 ABSTRACT Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics. Particularly, the PD-L1 antibody therapy has shown the efficiency in blocking membrane PD-L1 and efficacy in treating some advanced carcinoma. However, this therapy has limited effects on many solid tumors, suspecting to be relevant to PD-L1 located in other cellular compartments, where they play additional roles and are associated with poor prognosis. In this review, we highlight the advances of 3 current strategies on PD-1/PD-L1 based immunotherapy, summarize cellular distribution of PD-L1, and review the versatile functions of intracellular PD-L1. The intracellular distribution and function of PD-L1 may indicate why not all antibody blockade is able to fully stop PD-L1 biological functions and effectively inhibit tumor growth. In this regard, gene silencing may have advantages over antibody blockade on suppression of PD-L1 sources and functions. Apart from cancer cells, PD-L1 silencing on host immune cells such as APC and DC can also enhance T cell immunity, leading to tumor clearance. Moreover, the molecular regulation of PD-L1 expression in cells is being elucidated, which helps identify potential therapeutic molecules to target PD-L1 production and improve clinical outcomes. Based on our understandings of PD-L1 distribution, regulation, and function, we prospect that the more effective PD-L1-based cancer immunotherapy will be combination therapies. INTRODUCTION Cancer immunotherapy is a specific method to eliminate cancer cells by enhancing or modulating the host immune system. The immune checkpoint molecules regulate the immune balance, and the neutralization of immunosuppressive checkpoints can lead to cancer elimination. Among these immune checkpoints, the blockade of programmed death-protein 1 (PD-1) and its ligands 1 and 2 (PD-L1/2), an intrinsic negative checkpoint, leads to one of the most successful immunotherapies by enhancing T cell immune responses against tumor cells. Currently, the blockade of PD-1/PD-L1 can be achieved via three methods: (1) antibody blockade, (2) gene silencing, and (3) small-molecule pathway inhibition. The commercial PD-L1 antibodies have shown tremendous success, in particular, for advanced cancers such as melanoma and non-small lung cancers (1, 2). Out of the three methods the gene silencing strategy is less studied but has now attracted more attention due to the approach of inhibiting PD-L1 pathways. The antibody-based treatment has shown in studies to be insufficient in all PD-L1 low expression cases, and even some PD-L1 overexpression cohort (1). Moreover, the overall response rate in most solid tumors is only around 20%. This deficiency suggests that deeper understanding of the PD-L1 mechanism is required. In addition, the cost of production and delivery, storage stability, and immunogenicity are also issues for the antibodies (3). Mechanically, the suppression of PD-L1 using gene silencing may be more efficient than antibody blockade, as a single interfering gene fragment is able to “switch off” the protein synthesis. This method is still regarded as a backup regimen for PD-L1 therapy due to the lack of commercialized products and other issues of gene/drug delivery. Other than direct PD-L1 gene silencing, the siRNAs can also benefit PD-L1 based treatment through regulating the involved expression signaling pathways, which can also be achieved by commercialized chemical inhibitors as well (4). These chemical inhibitors, with definite chemical structures, can offer benefits in terms of pharmacokinetics, druggability, and cost control. The drawback of this method is that the regulation downregulates PD-L1 molecules indirectly, resulting in a possible increase in time require for the downregulating pathway signal molecules to communicate to the PD-L1 molecules. In addition, small molecules of pathway inhibitors may induce drug resistance (4). Recent studies have revealed that the PD-L1 molecules have a broad distribution in and outside cells. PD-L1 can be located extracellularly, intracellularly, and on the cell membrane. Elucidating the functions of PD-L1 at different locations and its transport could lead to deeper understanding of these treatment strategies, thus guide the choice of therapeutic approach. However, both the PD-L1 distribution and subsequent selection of a proper therapeutic regimen have not been clearly discussed. Herein, we have firstly summarized the current studies on PD-L1 distribution in this review article. Subsequently, the PD-L1 based immunotherapies in relation to these three methods are reviewed and compared. We have then provided our opinions regarding how to choose a personalized strategy for more effective PD-L1 based cancer therapy in the final prospective section. BACKGROUND OF PD-1/PD-L1 BASED CANCER IMMUNOTHERAPY As one of the major threats to public health worldwide, cancer is responsible for millions of deaths annually, with a high morbidity (5). Simultaneously, trillions of dollars spent in cancer treatment further intensify the pressure upon our society and patient families (6). Since the last decade, the immunotherapy has become an efficient cancer treatment. With the onset of tumor, multiple immune resistance mechanisms, such as local immune evasion, tolerance induction, and immune edition, are developed for tumor escape from immune surveillance (7, 8). Thus, immunotherapy strategies against cancers are proposed to stimulate the effectors and/or counteract inhibitory and suppressive mechanisms (9), including the regulation of immune cells (vaccine and T cell engineering), cytokines (ILs, IFNs, TGFs, TNFs, etc.) and immune checkpoints. Recent discovery of immunosuppressive checkpoints, such as CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and PD-1, provides a very successful regimen to cancer immunotherapy (10, 11), which has been awarded Nobel Prize in 2018. PD-L1, also known as CD274 and B7-H1, is a transmembrane protein commonly expressed on the surface of antigen presenting cells and tumor cells. PD-L1 specifically binds to its receptor, PD-1, which is expressed on the surface of immune-related lymphocytes, such as T cells, B cells, and myeloid cells (11, 12). In some solid or blood tumors, the PD-L1 can also bind to the PD-1 expressed on tumor cell surface (13–15). As shown in Figure 1, the binding of PD-L1 to PD-1 is able to activate the down-stream signaling of PD-1 receptor in T cells, thus inhibiting the proliferation, cytokine generation and release, and cytotoxicity of T cells. This down-regulation of immunity will prevent autoimmunity and chronic infection, many tumor cells also use this mechanism to protect themselves from immune attack, causing the so-called tumor immune evasion (12). PD-L1 mediated tumor immune resistance includes innate resistance caused by endogenously constitutive PD-L1 expression, and adaptive resistance caused by exogenously stimuli-inducible PD-L1 expression (16). Inhibition of either PD-1 or PD-L1 will enhance T cell responses to cancer. This approach is known as PD-1/PD-L1 based immunotherapy. [Figure: Immunotherapy based on PD-1/PD-L1 interaction. (A) The interaction of PD-1/PD-L1 causes tumor immune tolerance. The PD-1/PD-L1 interaction stimulates the downstream signals to suppress T cell activation, resulting in tumor cell survival. (B) Breakdown of the PD-1/PD-L1 interaction reactivates T cells and related immune responses. Without the PD-1/PD-L1 interaction, the suppression signal is removed, thus leading to T cell activation, proliferation, and cytokine generation and tumor cell elimination. KIR, killer-cell immunoglobulin-like receptor.] Based on this understanding, six antagonists have been developed and successfully approved by FDA. All of the approved antagonists are monoclonal antibodies, all have the ability to bind PD-1 or PD-L1. Notably, these antibodies demonstrate remarkably durable and persistent responses, with some patients remaining free from cancer progression